Detection of oseltamivir-resistant pandemic influenza A(H1N1)pdm2009 in Brazil: can community transmission be ruled out?

PLoS One. 2013 Nov 11;8(11):e80081. doi: 10.1371/journal.pone.0080081. eCollection 2013.

Abstract

Although surveillance efforts that monitor the emergence of drug-resistant strains of influenza are critical, systematic analysis is overlooked in most developing countries. We report on the occurrence of strains of pandemic influenza A(H1N1)pdm09 with resistance and decreased susceptibility to oseltamivir (OST) in Brazil in 2009, 2011 and 2012. We found 7 mutant viruses, 2 with the mutation S247N and other 5 with the mutation H275Y. Most of these viruses were from samples concentrated in the southern region of Brazil. Some of these resistant viruses were detected prior to the initiation of OST treatment, suggesting that community transmission of mutant viruses may exist. Moreover, we show that one of these OST-resistant (H275Y) strains of A(H1N1)pdm09 was discovered in the tri-border region between Brazil, Argentina and Paraguay, highlighting that this strain could also be found in other Latin American countries. Our findings reinforce the importance of enhanced antiviral resistance surveillance in Brazil and in other Latin American countries to confirm or rule out the community transmission of OST-resistant strains of A(H1N1)pdm09.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Animals
  • Antiviral Agents / therapeutic use
  • Brazil / epidemiology
  • Child
  • Child, Preschool
  • Dogs
  • Drug Resistance, Viral / drug effects
  • Drug Resistance, Viral / genetics*
  • Epidemiological Monitoring
  • Humans
  • Infant
  • Infant, Newborn
  • Influenza A Virus, H1N1 Subtype / genetics*
  • Influenza A Virus, H1N1 Subtype / isolation & purification
  • Influenza, Human / drug therapy
  • Influenza, Human / epidemiology
  • Influenza, Human / transmission*
  • Influenza, Human / virology
  • Madin Darby Canine Kidney Cells
  • Middle Aged
  • Mutation
  • Neuraminidase / antagonists & inhibitors
  • Neuraminidase / genetics*
  • Oseltamivir / therapeutic use
  • Viral Proteins / antagonists & inhibitors
  • Viral Proteins / genetics*

Substances

  • Antiviral Agents
  • Viral Proteins
  • Oseltamivir
  • Neuraminidase

Grants and funding

The work was supported by Instituto Oswaldo Cruz/Fiocruz (www.ioc.fiocruz.br) and Brazilian Ministry of Health/Decit and SVS (http://dtr2001.saude.gov.br/sctie/decit/index.htm). MMS was supported in part by individual research grants from CNPq (www.cnpq.br). MMS and TLMS used, in part, individual research grants from FAPERJ (www.faperj.br) and CNPq. Thanks are also due to IOC/Fiocruz for providing PCR and NFR fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.